Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
News about CVS Health Corporation (NYSE: CVS) covers developments across its roles in retail pharmacy, pharmacy benefit management, health insurance and health care delivery. Company press releases and related disclosures highlight how CVS Health communicates financial performance, strategic priorities, governance updates and community initiatives to investors, customers and the public.
Investors following CVS stock can find news on quarterly and full-year earnings announcements, financial guidance updates and Investor Day presentations. For example, CVS Health has issued press releases discussing results for specific quarters, updating full-year financial guidance and providing outlooks for future years, including projections for revenues, operating income, adjusted operating income, GAAP diluted earnings (loss) per share and adjusted EPS. These communications often appear in conjunction with Form 8-K filings that furnish the underlying press releases.
Corporate governance and leadership changes are another recurring news theme. CVS Health has announced Board decisions such as appointing its President and Chief Executive Officer, J. David Joyner, to the additional role of Chair of the Board, and it has used both press releases and Form 8-K filings to describe these actions and related Board structures.
Operational and community-focused news items describe how CVS Health engages with public health and local organizations. Examples include offering the measles-mumps-rubella (MMR) vaccine at select CVS Pharmacy and MinuteClinic locations in South Carolina during a measles outbreak, and the CVS Health Foundation’s grants to the American Diabetes Association to expand a maternal diabetes program in New York City. Other stories highlight investments in affordable housing projects and the company’s reported economic impact across U.S. states.
Visitors to this news page can review these types of announcements to understand how CVS Health presents its strategy, financial outlook, health services, community partnerships and responses to health challenges over time.
CVS (NYSE:CVS) became an Official Health and Wellness Partner of the U.S. Soccer Federation and the National Women's Soccer League on Feb 19, 2026, backing a multi-year program to develop community multi-use soccer fields in select U.S. markets through 2028.
The sponsorship also includes club partnerships with Washington Spirit, Seattle Reign FC and Kansas City Current and community programs amplified by athletes and ambassadors.
CVS Health (NYSE: CVS) announced a $5 million scholarship program to support students pursuing a Doctor of Pharmacy (PharmD) at Xavier University of Louisiana and the University of Louisiana at Monroe.
The program aims to reduce financial barriers, strengthen Louisiana's pharmacy workforce, and expand access to care, starting in the 2026-27 academic year.
CVS Health (NYSE: CVS) reported fourth-quarter and full-year 2025 results with total revenues of $105.7B (Q4, +8.2% YoY) and a record $402.1B for the year (+7.8% YoY). GAAP diluted EPS was $2.30 in Q4 and $1.39 for the year; adjusted EPS was $1.09 in Q4 and $6.75 for the year.
The company generated $10.6B of operating cash flow in 2025, completed pharmacy reimbursement transitions, and cited $5.7B goodwill impairment and ~$1.2B legacy litigation charges that reduced operating income. 2026 adjusted EPS guidance: $7.00–$7.20; GAAP EPS guidance: $5.94–$6.14.
CVS (NYSE: CVS) announced that about 9,000 CVS Pharmacy locations now accept TrumpRx discount cards, allowing eligible patients to apply manufacturer-determined savings at the pharmacy counter.
CVS notes its 27,000 community pharmacists can help customers, and that CVS Specialty and NovoCare support reduced pricing for fertility medications via the TrumpRx Fertility program.
Aetna (NYSE: CVS) was named Press Ganey's inaugural Health Plan of the Year at the Human Experience (HX26) Conference on Feb. 5, 2026. The award recognizes sustained excellence in member experience, quality performance and provider collaboration, citing programs like the HX Exchange partnership with Press Ganey.
CVS (NYSE: CVS) will add osteoporosis biosimilars Ospomyv and Stoboclo and generic teriparatide (Bonsity, Tymlos) to major national commercial template formularies effective April 1, 2026, replacing Prolia and Forteo to expand lower-cost options.
The preferred biosimilar approach is stated to be over 50% lower cost per prescription; CVS Caremark cites $1.5 billion in gross savings to date and a 96% Humira-to-biosimilar transition rate for client members.
Aetna (NYSE: CVS) announced a fully digital benefits onboarding experience for four million members for the 2026 welcome season on Feb. 5, 2026. The program uses enhanced messaging, moving from SMS to RCS, to reduce clicks and avoid mandatory app downloads.
Aetna reported an 80% increase in member engagement and a 26% reduction in opt-out rates for RCS-supported interactions and plans to expand RCS across discharge, recovery, and chronic condition management in 2026.
CVS Health (NYSE: CVS) is activating emergency measures ahead of a major winter storm expected to affect much of the U.S. over the next few days. The company is urging pharmacy patients to refill and pick up prescriptions and is supplying stores with extra emergency items such as water, batteries and first aid products.
CVS Caremark is enabling one-time emergency 10-day refills where states have declared emergencies. CVS Specialty and Aetna clinical teams will contact impacted patients and members to arrange alternate deliveries and expanded access to emergency care and mental health support. Store closures will follow local orders and phone lines will be rerouted as needed.
CVS Health (NYSE:CVS) announced initiatives to simplify care and lower costs, highlighting Aetna prior-authorization reforms, broader access programs, and pharmacy savings. Key metrics: approves >95% of eligible prior authorizations within 24 hours, 77% of electronic prior authorizations completed in real time (target >80% by year-end), prior-authorization bundling across cancer, musculoskeletal and IVF pathways, and embedding nurses in 17 major health systems to cut 30-day readmissions and length of stay by 5%. Pharmacy actions include a Humira alternative that generated $1.3B client savings and Caremark delivering rebate savings at the counter for 25M members.
CVS Health (NYSE: CVS) will hold a conference call with analysts and investors on Tuesday, February 10, 2026 at 8:00 a.m. ET to discuss fourth quarter and full year 2025 financial results. An audio webcast will be available live and archived for one year on the company's Investor Relations website at investors.cvshealth.com.